{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T03:55:27Z","timestamp":1793850927650,"version":"4.6.1"},"reference-count":30,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2018,3,1]]},"DOI":"10.1001\/jamacardio.2017.5205","type":"journal-article","created":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T12:31:05Z","timestamp":1517401865000},"page":"225","source":"Crossref","is-referenced-by-count":601,"title":["Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks"],"prefix":"10.1001","volume":"3","author":[{"given":"Theingi","family":"Aung","sequence":"first","affiliation":[{"name":"Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, England"},{"name":"Medical Research Council Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, England"},{"name":"Department of Endocrinology, Royal Berkshire Hospital, Reading, England"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Halsey","sequence":"additional","affiliation":[{"name":"Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, England"},{"name":"Medical Research Council Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, England"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daan","family":"Kromhout","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, University of Groningen, Groningen, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hertzel C.","family":"Gerstein","sequence":"additional","affiliation":[{"name":"Department of Medicine McMaster University, Hamilton Health Sciences, Hamilton, Ontario, Canada"},{"name":"Population Health Research Institute, McMaster University, Hamilton Health Sciences, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Marchioli","sequence":"additional","affiliation":[{"name":"Cardiovascular Renal Metabolic Therapeutic Area, Medical Strategy and Science, Therapeutic Science and Strategy Unit, Quintiles, Milan, Italy"},{"name":"Department of Cardiovascular Research, IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Tavazzi","sequence":"additional","affiliation":[{"name":"Maria Cecilia Hospital, GVM Care & Research, ES Health Science Foundation, Cotignola, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna M.","family":"Geleijnse","sequence":"additional","affiliation":[{"name":"Division of Human Nutrition, Wageningen University, Wageningen, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Rauch","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Herzinfarktforschung Ludwigshafen, Ludwigshafen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Ness","sequence":"additional","affiliation":[{"name":"National Institute for Health Research, Bristol Biomedical Research Centre, University Hospitals Bristol National Health Service Foundation Trust, University of Bristol, Bristol, England"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Galan","sequence":"additional","affiliation":[{"name":"Nutritional Epidemiology Research Team, Sorbonne Paris Cit\u00e9 Epidemiology and Biostatistics Research Center, Bobigny, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily Y.","family":"Chew","sequence":"additional","affiliation":[{"name":"Division of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackie","family":"Bosch","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, McMaster University, Hamilton Health Sciences, Hamilton, Ontario, Canada"},{"name":"School of Rehabilitation Science, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rory","family":"Collins","sequence":"additional","affiliation":[{"name":"Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, England"},{"name":"Medical Research Council Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, England"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Lewington","sequence":"additional","affiliation":[{"name":"Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, England"},{"name":"Medical Research Council Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, England"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Armitage","sequence":"additional","affiliation":[{"name":"Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, England"},{"name":"Medical Research Council Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, England"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Clarke","sequence":"additional","affiliation":[{"name":"Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, England"},{"name":"Medical Research Council Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, England"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Omega-3 Treatment Trialists\u2019 Collaboration","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"19","key":"hoi170076r1","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1056\/NEJM198505093121901","article-title":"The inverse relation between fish consumption and 20-year mortality from coronary heart disease.","volume":"312","author":"Kromhout","year":"1985","journal-title":"N Engl J Med"},{"issue":"4","key":"hoi170076r2","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1017\/S1368980011002254","article-title":"Fish consumption and CHD mortality: an updated meta-analysis of seventeen cohort studies.","volume":"15","author":"Zheng","year":"2012","journal-title":"Public Health Nutr"},{"issue":"4","key":"hoi170076r3","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1093\/eurheartj\/ehr362","article-title":"Fish oil and omega-3 fatty acids in cardiovascular disease: do they really work?","volume":"33","author":"Kromhout","year":"2012","journal-title":"Eur Heart J"},{"issue":"8666","key":"hoi170076r4","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S0140-6736(89)90828-3","article-title":"Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: Diet and Reinfarction Trial (DART).","volume":"2","author":"Burr","year":"1989","journal-title":"Lancet"},{"issue":"2","key":"hoi170076r5","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/sj.ejcn.1601539","article-title":"Lack of benefit of dietary advice to men with angina: results of a controlled trial.","volume":"57","author":"Burr","year":"2003","journal-title":"Eur J Clin Nutr"},{"issue":"9177","key":"hoi170076r6","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S0140-6736(99)07072-5","article-title":"Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial.","volume":"354","author":"GISSI-Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico)","year":"1999","journal-title":"Lancet"},{"issue":"9645","key":"hoi170076r7","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/S0140-6736(08)61239-8","article-title":"Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial.","volume":"372","author":"Tavazzi","year":"2008","journal-title":"Lancet"},{"issue":"21","key":"hoi170076r8","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1056\/NEJMoa1003603","article-title":"N-3 fatty acids and cardiovascular events after myocardial infarction.","volume":"363","author":"Kromhout","year":"2010","journal-title":"N Engl J Med"},{"issue":"5","key":"hoi170076r9","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1097\/HJR.0b013e328339cc70","article-title":"A randomized clinical trial on N-3 polyunsaturated fatty acids supplementation and all-cause mortality in elderly men at high cardiovascular risk.","volume":"17","author":"Einvik","year":"2010","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"issue":"4","key":"hoi170076r10","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1056\/NEJMoa1203859","article-title":"N-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.","volume":"367","author":"Bosch","year":"2012","journal-title":"N Engl J Med"},{"issue":"21","key":"hoi170076r11","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1161\/CIRCULATIONAHA.110.948562","article-title":"OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction.","volume":"122","author":"Rauch","year":"2010","journal-title":"Circulation"},{"key":"hoi170076r12","doi-asserted-by":"publisher","first-page":"c6273","DOI":"10.1136\/bmj.c6273","article-title":"Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial.","volume":"341","author":"Galan","year":"2010","journal-title":"BMJ"},{"issue":"9","key":"hoi170076r13","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1177\/2047487315613664","article-title":"N-3 fatty acids in patients with multiple cardiovascular risk factors.","volume":"23","author":"Risk and Prevention Study Collaborative Group","year":"2016","journal-title":"Eur J Prev Cardiol"},{"issue":"9567","key":"hoi170076r14","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","article-title":"Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis.","volume":"369","author":"Yokoyama","year":"2007","journal-title":"Lancet"},{"issue":"5","key":"hoi170076r15","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1001\/jamainternmed.2014.328","article-title":"Effect of long-chain ?-3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial.","volume":"174","author":"Bonds","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"4","key":"hoi170076r16","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/S0002-9343(01)01114-7","article-title":"N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials.","volume":"112","author":"Bucher","year":"2002","journal-title":"Am J Med"},{"issue":"10","key":"hoi170076r17","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1001\/2012.jama.11374","article-title":"Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis.","volume":"308","author":"Rizos","year":"2012","journal-title":"JAMA"},{"issue":"9","key":"hoi170076r18","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1001\/archinternmed.2012.262","article-title":"Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta-analysis of randomized, double-blind, placebo-controlled trials.","volume":"172","author":"Kwak","year":"2012","journal-title":"Arch Intern Med"},{"issue":"7","key":"hoi170076r19","doi-asserted-by":"publisher","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Med"},{"issue":"9740","key":"hoi170076r21","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/S0140-6736(10)60445-X","article-title":"Cardiovascular effects of marine omega-3 fatty acids.","volume":"376","author":"Saravanan","year":"2010","journal-title":"Lancet"},{"issue":"13","key":"hoi170076r22","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1093\/eurheartj\/ehr499","article-title":"Effects of n-3 fatty acids on major cardiovascular events in statin users and non-users with a history of myocardial infarction.","volume":"33","author":"Eussen","year":"2012","journal-title":"Eur Heart J"},{"issue":"4","key":"hoi170076r23","first-page":"CD003177","article-title":"Omega 3 fatty acids for prevention and treatment of cardiovascular disease.","volume":"18","author":"Hooper","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"hoi170076r25","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/s13063-016-1354-9","article-title":"Cost-effective recruitment methods for a large randomised trial in people with diabetes: a study of cardiovascular events in diabetes (ASCEND).","volume":"17","author":"Aung","year":"2016","journal-title":"Trials"},{"issue":"1","key":"hoi170076r26","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.cct.2011.09.009","article-title":"The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease.","volume":"33","author":"Manson","year":"2012","journal-title":"Contemp Clin Trials"},{"issue":"29","key":"hoi170076r28","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","article-title":"2016 guidelines on cardiovascular disease prevention in clinical practice.","volume":"37","author":"Piepolo","year":"2016","journal-title":"Eur Heart J"},{"issue":"39","key":"hoi170076r29","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS guidelines for the management of dyslipidaemias.","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"issue":"15","key":"hoi170076r30","doi-asserted-by":"publisher","first-page":"e867","DOI":"10.1161\/CIR.0000000000000482","article-title":"Omega-3 polyunsaturated fatty acid (fish oil) supplementation and the prevention of clinical cardiovascular disease: a science advisory from the American Heart Association.","volume":"135","author":"Siscovick","year":"2017","journal-title":"Circulation"},{"key":"hoi170076r20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/med\/9780199204854.003.020303_update_002","volume-title":"Oxford Textbook of Medicine","author":"Baigent","year":"2010","edition":"5th ed"},{"key":"hoi170076r24","unstructured":"Agency for Heathcare Research and Quality. Omega-3 fatty acids and cardiovascular disease: an updated systemative review; evidence report\/technology assessment no. 223. https:\/\/effectivehealthcare.ahrq.gov\/sites\/default\/files\/related_files\/fatty-acids-cardiovascular-disease_executive.pdf. Accessed December 19, 2017."},{"key":"hoi170076r27","unstructured":"US National Library of Medicine. Outcomes study to assess STatin Residual risk reduction with EpaNova in hiGh CV risk patienTs with Hypertriglyceridemia (STRENGTH), 2014. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02104817. Accessed December 15, 2017."}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2670752","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,26]],"date-time":"2020-10-26T14:29:33Z","timestamp":1603722573000},"score":1,"resource":{"primary":{"URL":"http:\/\/cardiology.jamanetwork.com\/article.aspx?doi=10.1001\/jamacardio.2017.5205"}},"subtitle":["Meta-analysis of 10 Trials Involving 77\u202f917 Individuals"],"short-title":[],"issued":{"date-parts":[[2018,3,1]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2017.5205","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3,1]]}}}